IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 1880 
Small font sizeDefault font sizeIncrease font size
Navigate Here
 »   Next article
 »   Previous article
 »   Table of Contents

Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded407    
    Comments [Add]    
    Cited by others 10    

Recommend this journal


Year : 2005  |  Volume : 37  |  Issue : 2  |  Page : 86-89

Coxibs: The new super aspirins or unsafe pain killers?

1 Pharmacology Division, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh-160 014, India
2 Department of Molecular and Medical Pharmacology, University of California, Los angeles, CA, USA

Correspondence Address:
S K Kulkarni
Pharmacology Division, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh-160 014
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0253-7613.15107

Rights and Permissions

The new generation of analgesics and antiinflammatory drugs, namely, the selective inhibitors of cyclooxygenase-2 (COX-2) enzymes, popularly known as Coxibs, have become a very popular class of drugs because of their gastro-sparing property. Coxibs were the widely prescribed drugs (nearly 8 million people round the globe take these drugs) until the recent setback with rofecoxib, which was withdrawn from the market by the innovator due to increased risk of heart attacks and strokes observed with its long-term use. The withdrawal of this popular NSAID has not only caused a great setback in the global market of coxibs but has also questioned the ethics involved in the toxicity testing and sharing of information with the end users of this new class of drugs. This article briefly reviews the developments in coxib theory, the clinical efficacy and safety of these agents in the light of the latest cardiovascular concerns.


Print this article     Email this article

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer | Privacy Notice
Online since 20th July '04
Published by Wolters Kluwer - Medknow